Michael Gilman is the CEO of a biotech startup showing early progress on a technology that was once thought to be impossible, but which may herald an entirely new class of oral medicines.

Almost every pill people take works by altering the activity of a protein. Something like 99 percent of medicines, in fact, are targeted against disease-causing proteins. That’s fine, as long as those small-molecule drugs — the chemicals that are made into pills — are able to lock into the nooks and crannies of disease-causing proteins. The problem is that a vast majority of proteins, something like 85 percent, don’t have these nooks and crannies. And that means they are undruggable with conventional medicines.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy